Literature DB >> 17349976

ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3.

Si-On Choi1, Young-Suk Cho, Hye-Lim Kim, Jong-Wan Park.   

Abstract

Hepcidin, a liver peptide, systemically inhibits iron utilization and is downregulated under hypoxic conditions. However, little is known about the mechanism underlying the hypoxic suppression of hepcidin. Here, we tested the possibility that HIF-1 and ROS are involved in hepcidin regulation. Hepcidin mRNA, pre-mRNA, and protein levels were reduced in mouse livers and in HepG2 cells after hypoxic incubation, and HIF-1 overexpression and knock-down studies showed that hepcidin regulation is independent of HIF-1. On the other hand, ROS levels were significantly elevated in hypoxic HepG2 cells, and anti-oxidants prevented the hypoxic down-regulation of hepcidin. Conversely, a prooxidant, H(2)O(2), suppressed hepcidin expression in these cells even in normoxia. Of the various transcription factors examined, C/EBPalpha and STAT-3 were found to dissociate from hepcidin promoter under hypoxia, but to become fully engaged after anti-oxidant treatment. These results suggest that ROS repress the hepcidin gene by preventing C/EBPalpha and STAT-3 binding to hepcidin promoter during hypoxia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17349976     DOI: 10.1016/j.bbrc.2007.02.137

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  40 in total

Review 1.  Synthetic and natural iron chelators: therapeutic potential and clinical use.

Authors:  Heather C Hatcher; Ravi N Singh; Frank M Torti; Suzy V Torti
Journal:  Future Med Chem       Date:  2009-12       Impact factor: 3.808

2.  Future alternative therapies for β-thalassemia.

Authors:  Stefano Rivella; Eliezer Rachmilewitz
Journal:  Expert Rev Hematol       Date:  2009-12-01       Impact factor: 2.929

3.  Hypoxia inhibits hepcidin expression in HuH7 hepatoma cells via decreased SMAD4 signaling.

Authors:  Timothy B Chaston; Pavle Matak; Katayoun Pourvali; Surjit K Srai; Andrew T McKie; Paul A Sharp
Journal:  Am J Physiol Cell Physiol       Date:  2011-02-02       Impact factor: 4.249

4.  Hypoxia-inducible factor-1alpha enhances haptoglobin gene expression by improving binding of STAT3 to the promoter.

Authors:  Mi-Kyung Oh; Hyo-Jung Park; Nam-Hoon Kim; Seon-Joo Park; In-Yang Park; In-Sook Kim
Journal:  J Biol Chem       Date:  2011-01-11       Impact factor: 5.157

Review 5.  Oxidative Stress in β-Thalassemia.

Authors:  Eitan Fibach; Mutaz Dana
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

6.  Differences in activation of mouse hepcidin by dietary iron and parenterally administered iron dextran: compartmentalization is critical for iron sensing.

Authors:  Alina Daba; Konstantinos Gkouvatsos; Giada Sebastiani; Kostas Pantopoulos
Journal:  J Mol Med (Berl)       Date:  2012-07-31       Impact factor: 4.599

7.  Function of the hemochromatosis protein HFE: Lessons from animal models.

Authors:  Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2008-12-07       Impact factor: 5.742

8.  Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3.

Authors:  Karuppaiyah Selvendiran; Anna Bratasz; M Lakshmi Kuppusamy; Mia F Tazi; Brian K Rivera; Periannan Kuppusamy
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

9.  Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors.

Authors:  Melanie Volke; Daniel P Gale; Ulrike Maegdefrau; Gunnar Schley; Bernd Klanke; Anja-Katrin Bosserhoff; Patrick H Maxwell; Kai-Uwe Eckardt; Christina Warnecke
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.